Author: Jason Curtis

Intensive care unit (ICU) referrals and admissions at a district general hospital (DGH) in light of the COVID-19 pandemic (2020)

Posted on by

Type of publication:
Conference abstract

Author(s):
*Blair J.; *Naughton E.; *Pradhan N.

Citation:
Intensive Care Medicine Experimental; 2020; vol. 8

Abstract:
Introduction: The COVID-19 pandemic has led to an increase in ICU referrals and admissions across the UK during 2020 [1]. Intensive care beds are a limited and expensive resource and decisions on patient admission are often very challenging [2]. Proformas help to standardise documentation and decision logging during patient referrals [3]. They provide easily accessible evidence in case of a future referral and allow audit of decision-making processes. A preliminary survey of doctors working in a DGH ICU was undertaken to assess the current referral and admission process in expectation of an increased volume of work.
Objective(s): As a result of the survey, three main areas for improvement were identified: 1. To maintain a record of all ICU referrals and decision-making processes 2. To reduce the time taken for documentation of referrals and admissions 3. To improve the quality and appropriateness of referrals from parent specialities Methods: A proforma was designed for dual use as a referral and admission document. All referrals were recorded on paper and staff received training on how to apply the proforma. After assessment of each referral, irrespective of admission outcome, a completed copy of the proforma was placed in both the patient's notes and a dedicated referrals folder. After one month, a further survey was designed to assess the response postimplementation of the proforma. All referrals made over a threemonth period between April and June 2020 were audited.
Result(s): The initial survey received 12 responses. Prior to the COVID-19 pandemic, documentation of any referral or admission took on average 10-15 minutes. All survey participants felt that referring teams did not have a good understanding of the role of ICU care and estimated that up to 40% of all referrals received were inappropriate. The follow-up survey received 14 responses. Implementation of the proforma reduced the time taken to document a referral or admission on average by 5-10 minutes. Twelve participants found the proforma a useful aid, helping to provide clear documentation and ease communication between ICU team members. Less than 9% of the referrals made between April and June 2020 were admitted to ICU with over 32% of referrals deemed unsuitable for further escalation. Approximately 50% of referrals were made by registrars, with 13% discussed by consultants. The median age of patients referred was 67.5 and the most common reason was for respiratory deterioration.
Conclusion(s): This quality improvement project successfully reduced the time taken to document ICU referrals and admissions. Use of a proforma has provided many benefits, including standardisation of documentation, decision logging and improvement of intra-and inter-team communication. Only a small proportion of patients referred to ICU have been suitable for admission. A teaching session is being designed so that referral information can be fed-back to parent specialties. Referrals will be reaudited after this. Data analysis of this project has been limited by incomplete proforma documentation from participating users.

Link to full-text [open access - no password required]

A Tidal volume calculator to improve lung protective ventilation in COVID-19 related Acute Respiratory Distress Syndrome (ARDS) (2020)

Posted on by

Type of publication:
Conference abstract

Author(s):
*Blair J.; *Hester S.; Baldwin A.; Ali T.

Citation:
Intensive Care Medicine Experimental; 2020; vol. 8

Abstract:
Introduction: Routine use of lower tidal volumes (TVs) for the mechanical ventilation of patients with ARDS results in decreased mortality and increases the number of days without ventilator use [1]. Severe COVID-19 pneumonia has been associated with the development of ARDS as characterised by the Berlin definition [2]. A multi-centre preliminary audit was undertaken to identify whether ventilated COVID-19 related ARDS patients were receiving optimal TVs, as recommended by the Faculty of Intensive Care Medicine (FICM) and Intensive Care Society (ICS) ARDS management guidelines [3]. Objective(s): As a result of the audit, three main areas for improvement were identified. 1. To achieve accurate calculations for ideal body weight (IBW) and target TV 2. To improve documentation of IBW and target TV 3. To achieve TVs no greater than 6 ml/kg Methods: A 'tidal volume calculator' tool was developed using Microsoft Excel, which was simple, colour coded and kept on all Intensive Care Unit (ICU) computer desktops. This tool was designed to use height to calculate IBW and, if the patient's height was unavailable, could also be utilised to calculate height from ulna length. IBW was subsequently used to calculate a target TV. Staff received training on how to apply the tool. Two snapshot audits were carried out in April and May 2020 at two ICUs. The first was conducted prior to the tool's introduction with the second two weeks after its implementation. All patients receiving mechanical ventilation, except those spontaneously breathing, were included. Data was extracted from patient notes, charts and ventilator settings. Result(s): The initial audit included 14 patients. Six patients did not have an IBW documented. Three patients had documented IBWs that were 12 kg, 15 kg and 23 kg greater than the weight calculated using the tool, leading to increased tidal volume targets. Only three patients were achieving TVs of 4-6 ml/kg. Eleven patients were achieving a TV greater than 6 ml/kg, with two of these achieving a TV of greater than 8 ml/kg. The follow-up audit included ten patients. This revealed that all patients had an IBW clearly documented. Moreover, nine patients were achieving TVs within 4-6 ml/kg, with only one patient found to be achieving a TV greater than 6 ml/kg. Conclusion(s): This audit cycle revealed that initially adherence to lung protective ventilation and documentation of IBW was poor. In some instances, documented IBW was vastly different to the calculated IBW, suggesting that in these situations actual body weight may have been used. In a time when clinicians were being redeployed to support ICU, this simple tool was shown to support staff by clearly calculating and displaying IBW and target TV for reference. This directly led to improved adherence to lung protective ventilation and optimisation of patient care. Limitations include that no consideration was made for overall patient outcome, and only a snapshot of achieved TVs from ventilators were recorded; daily/weekly trends were not studied.

Link to full-text [open acces - no password required]

Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial (2021)

Posted on by

Type of publication:
Journal article

Author(s):
Morgan R.D.; Jayson G.C.; Clamp A.R.; McNeish I.A.; Krell J.; Cook A.D.; James E.C.; Lord R.; Dark G.; Glasspool R.M.; Parkinson C.; Poole C.J.; Hall M.; Gallardo-Rincon D.; Lockley M.; Essapen S.; Summers J.; Anand A.; *Zachariah A.; Williams S.; Jones R.; Scatchard K.; Walther A.; Kim J.-W.; Sundar S.; Ledermann J.A.

Citation:
The Lancet Oncology; Feb 2021; vol. 22 (no. 2); p. 277-288

Abstract:
Background: Platinum-based neoadjuvant chemotherapy followed by delayed primary surgery (DPS) is an established strategy for women with newly diagnosed, advanced-stage epithelial ovarian cancer. Although this therapeutic approach has been validated in randomised, phase 3 trials, evaluation of response to neoadjuvant chemotherapy using Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST), and cancer antigen 125 (CA125) has not been reported. We describe RECIST and Gynecologic Cancer InterGroup (GCIG) CA125 responses in patients receiving platinum-based neoadjuvant chemotherapy followed by DPS in the ICON8 trial. Method(s): ICON8 was an international, multicentre, randomised, phase 3 trial done across 117 hospitals in the UK, Australia, New Zealand, Mexico, South Korea, and Ireland. The trial included women aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-2, life expectancy of more than 12 weeks, and newly diagnosed International Federation of Gynecology and Obstetrics (FIGO; 1988) stage IC-IIA high-grade serous, clear cell, or any poorly differentiated or grade 3 histological subtype, or any FIGO (1988) stage IIB-IV epithelial cancer of the ovary, fallopian tube, or primary peritoneum. Patients were randomly assigned (1:1:1) to receive intravenous carboplatin (area under the curve [AUC]5 or AUC6) and intravenous paclitaxel (175 mg/m2 by body surface area) on day 1 of every 21-day cycle (control group; group 1); intravenous carboplatin (AUC5 or AUC6) on day 1 and intravenous dose-fractionated paclitaxel (80 mg/m2 by body surface area) on days 1, 8, and 15 of every 21-day cycle (group 2); or intravenous dose-fractionated carboplatin (AUC2) and intravenous dose-fractionated paclitaxel (80 mg/m2 by body surface area) on days 1, 8, and 15 of every 21-day cycle (group 3). The maximum number of cycles of chemotherapy permitted was six. Randomisation was done with a minimisation method, and patients were stratified according to GCIG group, disease stage, and timing and outcome of cytoreductive surgery. Patients and clinicians were not masked to group allocation. The scheduling of surgery and use of neoadjuvant chemotherapy were determined by local multidisciplinary case review. In this post-hoc exploratory analysis of ICON8, progression-free survival was analysed using the landmark method and defined as the time interval between the date of pre-surgical planning radiological tumour assessment to the date of investigator-assessed clinical or radiological progression or death, whichever occurred first. This definition is different from the intention-to-treat primary progression-free survival analysis of ICON8, which defined progression-free survival as the time from randomisation to the date of first clinical or radiological progression or death, whichever occurred first. We also compared the extent of surgical cytoreduction with RECIST and GCIG CA125 responses. This post-hoc exploratory analysis includes only women recruited to ICON8 who were planned for neoadjuvant chemotherapy followed by DPS and had RECIST and/or GCIG CA125-evaluable disease. ICON8 is closed for enrolment and follow-up, and registered with ClinicalTrials.gov, NCT01654146. Finding(s): Between June 6, 2011, and Nov 28, 2014, 1566 women were enrolled in ICON8, of whom 779 (50%) were planned for neoadjuvant chemotherapy followed by DPS. Median follow-up was 29.5 months (IQR 15.6-54.3) for the neoadjuvant chemotherapy followed by DPS population. Of 564 women who had RECIST-evaluable disease at trial entry, 348 (62%) had a complete or partial response. Of 727 women who were evaluable by GCIG CA125 criteria at the time of diagnosis, 610 (84%) had a CA125 response. Median progression-free survival was 14.4 months (95% CI 9.2-28.0; 297 events) for patients with a RECIST complete or partial response and 13.3 months (8.1-20.1; 171 events) for those with RECIST stable disease. Median progression-free survival for women with a GCIG CA125 response was 13.8 months (95% CI 8.8-23.4; 544 events) and 9.7 months (5.8-14.5; 111 events) for those without a GCIG CA125 response. Complete cytoreduction (R0) was achieved in 187 (56%) of 335 women with a RECIST complete or partial response and 73 (42%) of 172 women with RECIST stable disease. Complete cytoreduction was achieved in 290 (50%) of 576 women with a GCIG CA125 response and 30 (30%) of 101 women without a GCIG CA125 response. Interpretation(s): The RECIST-defined radiological response rate was lower than that frequently quoted to patients in the clinic. RECIST and GCIG CA125 responses to neoadjuvant chemotherapy for epithelial ovarian cancer should not be used as individual predictive markers to stratify patients who are likely to benefit from DPS, but instead used in conjunction with the patient's clinical capacity to undergo cytoreductive surgery. A patient should not be denied surgery based solely on the lack of a RECIST or GCIG CA125 response. Funding(s): Cancer Research UK, UK Medical Research Council, Health Research Board in Ireland, Irish Cancer Society, and Cancer Australia.

Altmetrics:

'Daycase parathyroidectomy: Time to change the norm?' (2020)

Posted on by

Type of publication:
Conference abstract

Author(s):
Chang J.; Neophytou C.; Howard E.; Houghton A.

Citation:
British Journal of Surgery; 2020; vol. 107 ; p. 37

Abstract:
Introduction: The most recent BAETs audit report of 2017 shows a surprisingly low rate of same-day discharge following parathyroidectomy (10%). In our unit we have developed a simple and safe protocol which allows same day discharge for almost all patients (95%). The 2017 BAETS report has 11,463 patients recorded for primary hyperparathyroidism. Following this simple protocol could save over 9,500 inpatient bed days.
Method(s): Demographics, histology, biochemistry and length of stay were identified for all patients undergoing parathyroidectomy for primary hyperparathyroidism between 01/01/2010 and 31/12/2019. Following surgery all patients were discharged on Calcichew D3 one tablet tds, with arrangements for serum calcium analysis and outpatient appointment at 7 and 10 days Results: We performed 264 parathyroid procedures during the study period. The cohort had a median age of 63 (range 15 – 90). Day-case procedures were carried out in 95% (n=249). 10 patients stayed 24 hours, 4 for 48 hours and 1 patient for 4 days (urgent parathyroidectomy following acute medical admission with symptomatic hypercalcaemia). 1 patient was admitted overnight for observation of bleeding wound (no return to theatre). The remainder were admitted for a mixture of social and anaesthetic reasons. 6 patients (2%) had 30 day morbidity: 2with symptoms of relative hypocalcaemia (not admitted), 1 patient with hypocalcaemia requiring intravenous calcium, 1 seroma, 1 patient presented with an exacerbation of COPD and 1 haematoma.
Conclusion(s): We have shown that same-day discharge after parathyroid surgery is safe and ought to become the norm in other units.

Link to full-text [no password required]

IMPACT. Operating Department Human Factors Training for the whole team (2020)

Posted on by

Type of publication:
Conference abstract

Author(s):
Allman T.; Schunke N.; Fenton C.; Branfield L.

Citation:
British Journal of Surgery; 2020; vol. 107 ; p. 14

Abstract:
Aims: We identified a gap in effective staff training and developed a novel truly multidisciplinary training day to capture the whole team and expose them to simulation in their usual environment amongst usual peers. Our aim was to maximise the impact factor of multidisciplinary operating department human factors training and utilise high fidelity simulation to expose unknown unknowns and improve theatre safety.
Method(s): Novel human factors training run onsite. On a rotational basis designated theatre lists are blocked for the mandatory training to ensure all members of the theatre teams can attend ranging from porters to consultants and team leaders. Line managers enforce attendance and feedback is collated. Anaesthesia retained oversight and organisation. 3 main sessions run in parallel by teams of multidisciplinary facilitators.

  1. WHO Steps to Safer Surgery: Trust 'STOP THE LINE' video and discussion.
  2. Raising concerns: discussion lead by consultant surgeon.
  3. Theatre simulation & debrief: High fidelity in the operating theatre.

Result(s): The training received exemplary feedback and review from all staff across specialties.Multiple gaps in knowledge, particularly the location of rarely used emergency equipment and drugs was exposed and this allowed for on the spot, high yield training. Candidate feedback revealed the impact of our training was maximised by the facilitation led by consultant surgeons. Conclusion(s): Human factors training is notoriously variable and limited. We've collaborated surgical, anaesthetic and theatre teams to deliver high impact and resourceful training by addressing the human factors that mould our own learning.

Link to full-text [no password required]

Laparoscopic ligation of inferior mesenteric artery (IMA) for the management of type II endoleak post endovascular aneurysm repair (EVAR) (2020)

Posted on by

Type of publication:
Conference abstract

Author(s):
*Mashar R.; *Gangwar A.; *McCloud J.; *Shawish E.

Citation:
British Journal of Surgery; 2020; vol. 107 ; p. 96-97

Abstract:
Aim: Type II endoleaks following EVAR are caused by patent aortic collaterals causing retrograde blood flow, with the IMA being involved in 45-85% of all cases. Transarterial embolization has been described as a management option, but with a high failure rate. We present laparoscopic ligation as an alternative therapeutic strategy, with both technical success and a favourable outcome.
Method(s): An 80-old hypertensive male was diagnosed with a type II endoleak post-EVAR. Shrinkage of the sac was seen initially from 58mm to 52mm on surveillance-computed tomography (CT) of the aorta at 6 months with apersistent type II endoleak involving the IMA and lumbar arteries. Surveillance at 18 months demonstrated a persistent endoleak with enlargement of the sac to 65 mm. After a failed attempt with arterial embolization, he underwent laparoscopic ligation of the IMA Results: The procedure time was 22 minutes and his length of stay was 2 days, with no signs or symptoms of bowel ischaemia. A CT at 2 weeks demonstrated sac shrinkage to 58 mm. Conclusion(s): There have been reports of persistent endoleaks being associated with adverse outcomes, with their primary management remaining controversial. IMA ligation has been associated with sac shrinkage in 65% of patients, an important prognostic factor, and there have been no reported complications thus far. Therefore, it should be strongly considered as an option for management of type II endoleaks in centres with both vascular and general surgical expertise being available

Link to full-text [no password required]

The annual usage of anaesthetic gases at the Shrewsbury and Telford Hospitals NHS Trust: the environmental impact and potential solutions (2020)

Posted on by

Type of publication:
Conference abstract

Author(s):
*Thompson T.; *Passey S.; *Mowatt C.

Citation:
British Journal of Surgery; 2020; vol. 107 ; p. 74-75

Abstract:
Aims: The NHS is responsible for 5.5% of the UK's net emissions, with anaesthetic gases comprising of 5% of hospital emissions. Shrewsbury and Telford hospitals (SaTH) are DGH's with 18 combined theatres, 9 at each site. The aim of this study was to evaluate the environmental impact of anaesthetic gases used by the trust and suggest possible improvements.
Method(s): Figures from October 2018-2019 supplied by the hospital pharmacy and compared using the RCoA Anaesthetic Impact Calculator. Costs obtained from pharmacy relating to the available anaesthetic gases and drugs.
Result(s): Over the past year SaTH has emitted the equivalent of 4,819,050kg of CO2 through its anaesthetic gases alone (these gases being sevoflurane, isoflurane, desflurane and nitrous oxide). Of these gases, sevoflurane is the greenest, while nitrous oxide is the worst offender. To give this an idea of scale, to offset, this would require the planting of 10915 trees, which would take up an area of 4-10 hectares of land.
Conclusion(s): We are recommending that SaTH stops using Nitrous oxide and Isoflurane, which is currently under consideration by the consultant body. We would discourage the use of desflurane, and where possible sevoflurane. Encourage the use of total intravenous anaesthetic (TIVA). We postulate this would save the trust aminimum of 5000 per year or 15000 per year with a 10% reduction in sevoflurane use. This would reduce our CO2 equivalent production by over 4.6 million kg.

Link to full-text [no password required]

The benefits of multidisciplinary human factors training in theatre (2020)

Posted on by

Type of publication:
Conference abstract

Author(s):
*Jones R.; *Branfield L.

Citation:
British Journal of Surgery; 2020; vol. 107 ; p. 75

Abstract:
Aims: The awareness of Human Factors (HF) and their role in patient safety is vital in the theatre environment.
The aim of this audit was therefore to assess the awareness of human factors within our theatre team during a Human Factors Training Course at a District General Hospital.
Method(s): The Human Factors Training Course started with a questionnaire assessing roles, experience, and awareness of HF. It also looked at staff morale. The course involved a presentation and 2 simulation scenarios in theatre. After completion, there was a post course questionnaire looking at awareness of human factors, effects on staff morale and impact on patient care.
Result(s): Of the respondents, experience varied from 1 to 10+ years. The pre-course awareness of HF averaged 6.1 out of 10. The opinions on morale averaged at 6.7 out of 10, and the effect of HF training on morale averaged 8.4 out of 10. All respondents believed that the course could improve patient care. Post course awareness of HF increased and staff morale also increased as a consequence of the course.
Conclusion(s): From the results we can see that the awareness of human factors within the cohort prior to training was relatively low. Post course, we can see an increase in terms of awareness of human factors. As well as providing a training opportunity, this course had a positive effect on staff morale, and vitally, it was thought that the course would have positive impact on patient care.

Link to full-text [no password required]

Reflective writing: Training and assessment (2016)

Posted on by

Type of publication:
Conference abstract

Author(s):
*Sizer, A; Chivers, C; Hayes, K; Khan, R

Citation:
Volume 123, Issue S2. Special Issue: Top Scoring Abstracts of the RCOG World Congress 2016, 20–22 June 2016, ICC Birmingham, United Kingdom

Abstract:
Reflective writing is a mandatory component of the annual review of competence progression (ARCP) for UK trainees in Obstetrics & Gynaecology.

It is often commented at ARCP panels that the quality of reflective writing is poor, but if challenged, consultants often find it difficult to say why.

It has been commented the reflection is not an intuitive process for doctors and is a skill that needs to be learnt. However, there is no clear learning process in the curriculum and an internet search revealed no course or training session that was available in the UK.

A reflective writing workshop was developed in the West Midlands Deanery. This was part of the monthly Symposium teaching for trainees at ST3‐5 level. Prior to the workshop, trainees were asked to submit a representative piece of reflective writing from their ePortfolio that had been submitted in the past 6 months so that the particular case or situation that they had reflected on was still fresh in their memory.

The workshop took the following format:

  • Trainees were split into small groups with a facilitator. They were given three pre-written reflective pieces to discuss, one poor, one average and one good. Following the small group work there was feedback to the entire group.
  • The lead facilitator then gave a presentation on reflective writing and models of reflection, particularly focussing on Gibbs reflective cycle and Rolfe's framework of reflection.
  • Trainees were then asked to work on writing a reflective piece in small groups on a mock scenario using a reflective model. There was further feedback and analysis by the whole group.
  • For the final session each trainee was asked to rewrite the reflection that they had previously submitted.
  • In order to assess the reflections pre- and post- workshop we devised a simple scoring system to take into account the key points of the reflective process, namely structure (ie was any particular model followed), length of the descriptive component, and then a subjective assessment of the descriptive and analytical components as well as the action plan. This gave a score of 10 for each reflective piece.
  • The workshop was very well received by the trainees. Interestingly, feedback from the trainees suggested that consultants needed to develop skills in the assessment of reflection.
    Data will be presented on the workshop and scoring system, including qualitative feedback data.

Triple Negative Male Breast Cancer (2021)

Posted on by

Type of publication:
Conference abstract

Author(s):
Qavi Q.; Alkistawi F.; Lesi O.; Asaad A.; Abdalla Al-Zawi A.S.; Abraham B.; Kumar S.; Ahmed R.; Barron M.; Arooj *Khan K.; Syed A.; Deniz E.; Abduljawad N.H.; Idaewor P.; Aladili Z.; Rasheed N.; Eldruki S.; Uddin A.

Citation:
European Journal of Surgical Oncology; Feb 2021; vol. 47 (no. 2)

Abstract:
Background: Male breast cancer (MBC) is a rare malignancy, may present at advanced disease stage. Triple negative breast cancer (TNBC) known to have the poorest prognosis of all other histological types of breast cancer. This paper presents a case of 71 years old gentleman diagnosed with TNBC. Material(s) and Method(s): A 71 years old male patient, presented with a right breast lump of a recent history also has chronic kidney disease, gastroesophageal reflux,, and excision of basal cell carcinoma of abdominal wall. Clinically he had a skin dent and apalpable 3cm lump underneath in the right breast axillary tail. Mammogramand breast US showed suspicious lesion in right breast axillary tail in additionto a suspicious lymph node in right axilla. Imaging guided core biopsies weretaken from the breast and axillary abnormalities. The histology revealed grade1 invasive ductal carcinoma NST, ER 0 and PR 0 and HER 2 negative. The Breast Multidisciplinary Team meeting advised for mastectomy and axillary clearance, this has been performed. The postoperative Pathomorphology report revealed 23 mm triple negative invasive ductal carcinoma NST, grade 1with Ki67 10%, T2N1M0. The postoperative MDT recommended annual surveillance with mammogram for 5 years. Result(s): MBC is very rare, it is the cause of 1% of all malignant diseases in men, andcauses < 1% of all breast cancers in both males and females.MBC is diagnosed at an average of 10 years later than the age at which breast cancer is diagnosed in females at 65 years of age.There are some reported risk factors associated with MBC as, cryptorchidism, family history, Klinefelter's syndrome, infertility and smoking. Also it has been reported that Only 1/3 of male patients who have BRCA1/2 mutation maydevelop malignancy of breast, pancreas and prostate. Similar to female breast cancer, the most histological type of male breast cancer is invasive ductalcarcinoma NST, and the oestrogen hormone receptors expression is greaterthan in females (up to 95%).Male triple negative breast cancer (MTNBC) is associated with aggressivedisease course, late stage of diagnosis, large size of the tumour size, hightumor histological grade, and high rate nodal disease, also is reported more in a younger patients.Mastectomy is the mainstay of surgical treatment and the triple-negative breast cancer generally has a better to chemotherapy than tumours with oestrogen hormone-receptor positive expression. Adjuvant radiotherapy is recommended, however it doesn't effect the cause-specific survival rate. Conclusion(s): MBC is uncommon entity, accounting for < 1% of all breast cancer diagnosed in both genders and the MTNBC still is rarer, and mastectomy is the mainstay of surgical treatment. in addition to chemotherapy and radiotherapy, however the later doesn't effect the cause-specific survival rate.